John Schorgl

Turning regulatory complexity into competitive advantage, Peytant has transformed from a startup with a vision into a company defining a new category of care. CEO John Schorgl will share the Peytant journey with its AMStent®System, which combines two proven materials – a nitinol stent and a human- sourced amniotic membrane -- in a fundamentally new way. More than a product story, this is about category creation -- using early, strategic regulatory engagement to differentiate and to establish a new option for care. For medtech leaders and investors, Peytant offers a compelling blueprint for building defensible innovation in today’s environment. This session will explore Peytant’s approach to turning regulatory hurdles into opportunity. Attendees will learn how the company brought its AMStent System, designed to expand options for patients with cancers of the lung, from concept to commercialization.